STOCK TITAN

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.

Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.

Our news collection prioritizes accuracy and timeliness, offering:

• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news

Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.

Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2024 financial results and provided a corporate update. The company prioritized EB-003 as its lead development candidate, a novel non-hallucinogenic neuroplastogenic molecule for treating severe mental health disorders. Preclinical results confirmed EB-003's oral bioavailability and significant brain exposure, supporting an expedited development strategy.

Key highlights include:

  • Expanded business development activities with multiple deals in advanced stages
  • Signed licensing agreement with Aries Science & Technology for radiation dermatitis product
  • Targeting IND filing for EB-003 by Q3 2025 and first-in-human trial by end of 2025
  • Q2 2024 net loss of $1.7 million ($0.23 per share) compared to $6.40 million ($3.04 per share) in Q2 2023
  • Cash-on-hand of $3.5 million as of June 30, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced promising preclinical results for EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The study revealed good oral bioavailability and significant brain exposure in rodent models, with a brain:plasma exposure ratio of ~1.5. EB-003 also demonstrated stability against human monoamine oxidase-A (MAO-A) and in various liver microsomes, unlike DMT and similar analogs.

Based on these results, Enveric is accelerating EB-003's evaluation in animal efficacy models. The company expects to file an IND application by Q3 2025 and initiate clinical development by the end of 2025. This advancement supports Enveric's patient-centered approach, aiming to develop non-hallucinogenic treatments with favorable pharmacological properties that enhance patient adherence and reduce treatment burden.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) and Aries Science & Technology have announced a licensing agreement for the clinical development of Enveric's patented radiation dermatitis topical product. This condition affects approximately two million cancer patients annually, with a market opportunity estimated at $400 million. The agreement includes potential milestone payments of up to $61 million and tiered royalties ranging from 2.5% to 10% on future sales for Enveric. Aries has nominated Dr. Hari Harikumar as Chairman-elect of a subsidiary formed to advance this opportunity. This partnership allows Enveric to focus on neuropsychiatric indications while Aries develops the cancer support care product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
Rhea-AI Summary

Enveric Biosciences announces that the United States Patent and Trademark Office has granted Patent No. 11,945,778 for its drug candidate EB-002. This new patent expands Enveric’s intellectual property by covering methods of treatment for a broad range of brain neurological disorders including sleep disorders, depression, substance-related disorders, and headaches.

EB-002, a next-generation psilocin prodrug initially developed for neuropsychiatric disorders such as anxiety, now holds three US patents covering its compositions, formulations, and methods of treatment. CEO Joseph Tucker highlights that this enhanced patent protection will help accelerate EB-002's clinical development and broaden its applicability to a wider patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has announced that it is prioritizing the development of its novel neuroplastogenic molecule, EB-003. EB-003 is designed to treat severe mental health disorders such as depression, anxiety, and addiction without causing the hallucinogenic effects often associated with psychedelic-based treatments. The company is advancing pre-clinical development and plans to meet with the FDA for a Pre-IND discussion in early 2025. EB-003 aims to overcome key issues identified by the FDA's advisory committee regarding hallucinogenic psychedelics, such as 'expectation bias' and the need for psychotherapy co-administration. Early data shows EB-003 can bind to the 5-HT2A receptor and induce neuroplasticity without significant hallucinogenic side effects in animal models, paving the way for further human clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a company focused on developing innovative neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders, announced its participation in the 2024 BIO International Convention. The event takes place in San Diego, CA, from June 3-6, 2024. Enveric aims to engage with potential investment and development partners to explore collaborations for its promising drug candidates. CEO Joseph Tucker emphasized the significant interest from strategic partners in the pharmaceutical industry for Enveric's drug discovery assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) reported financial and corporate results for the first quarter of 2024, ending March 31. The company unveiled seven classes of novel drug candidates from its Psybrary™ and PsyAI™ platforms. A business development campaign resulted in seven non-binding term sheets with four strategic partners, potentially totaling $410 million in milestone payments plus future royalties. Enveric's lead drug candidate, EB-003, is advancing towards an IND application and Phase 1 clinical trial. Proceeds from warrant exercises and investment options raised $4.5 million. The company's net loss for Q1 2024 was $2.46 million, with cash-on-hand at $6.36 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
-
Rhea-AI Summary

Enveric Biosciences, Inc (ENVB) signed a non-binding term sheet with an undisclosed biotechnology company for the exclusive license to patented methods of treating breast and other cancers using cannabinoids in combination with chemotherapeutic drugs. The licensee will receive an exclusive global license, assume responsibility for development, and pay Enveric up to $61 million in milestones and royalties. The agreement aims to advance novel treatment regimens for cancer patients, with a potential impact on breast and other cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.11%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) provided a corporate update, highlighting the selection of lead candidate EB-003 for mental health disorders. The company advanced preclinical activities for EB-002, signed term sheets for out-licensing compounds, expanded its intellectual property portfolio, and reported financial results for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
Rhea-AI Summary
Enveric Biosciences (ENVB) has signed two non-binding term sheets with an undisclosed biotechnology company to potentially out-license cannabinoid-COX-2 conjugate compounds for joint disease treatment. The agreements could lead to milestone payments totaling up to $82 million, with royalty rates ranging from 0.25% to 10% on future sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
none
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

2.89M
2.47M
0.07%
7.16%
64.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES